Tesamorelin is a ghrh analog with a development status of "fda-approved (branded form)". The Institute rates the strength of its published evidence as strong. A stabilized GHRH analog approved for HIV-associated lipodystrophy, with visceral-fat reduction demonstrated in phase 3 trials.
The distinction that matters most when reading about Tesamorelin is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Sample sizes in the Tesamorelin literature are small enough that individual studies should be read as hypothesis-generating rather than conclusive. Effect sizes reported in small trials are systematically inflated, and the pattern is well documented across pharmacology generally.
The Institute has independently tested 1 Tesamorelin sample from 1 company. 0% met their label claims on purity and content. Measured purity ranged from 57.8% to 57.8%, averaging 57.8%. 1 sample failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
